Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Neoadjuvant anti-tumor vaccination prior to surgery enhances survival

Figure 1

Neoadjuvant P/B vaccination enhances delay in tumor growth following debulking surgery. (A) Schematic of experiment design. BALB/c mice bearing AB1-HA tumor received PR8 prime vaccine (day 10) and rMVA-HA boost vaccine (day 17) alone, in combination with surgery (day 18) and tumor growth and overall survival compared to surgery only or sham surgery control groups. (B) Survival and growth curves showing significant survival benefit with combined therapy. (C-D) An increase in the proportion (C) and function (D) of HA-specific CD8 T cells was only observed in the spleens of vaccinated mice on day 21. **p < 0.01, ***p < 0.001. dLN = draining lymph node. ndLN = non-draining lymph node. Data = mean + SEM.

Back to article page